78 related articles for article (PubMed ID: 19148499)
21. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
22. Characteristics of EGFR family-mediated HRG signals in human ovarian cancer.
Campiglio M; Ali S; Knyazev PG; Ullrich A
J Cell Biochem; 1999 Jun; 73(4):522-32. PubMed ID: 10733345
[TBL] [Abstract][Full Text] [Related]
23. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
24. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
25. EGFR activity in HER-2 over-expressing metastatic breast cancer: evidence for simultaneous phosphorylation of Her-2/neu and EGFR.
Gschwantler-Kaulich D; Hudelist G; Koestler WJ; Czerwenka K; Mueller R; Helmy S; Ruecklinger E; Kubista E; Singer CF
Oncol Rep; 2005 Aug; 14(2):305-11. PubMed ID: 16012707
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
Esteva FJ; Sahin AA; Smith TL; Yang Y; Pusztai L; Nahta R; Buchholz TA; Buzdar AU; Hortobagyi GN; Bacus SS
Cancer; 2004 Feb; 100(3):499-506. PubMed ID: 14745865
[TBL] [Abstract][Full Text] [Related]
27. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
[TBL] [Abstract][Full Text] [Related]
28. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.
DiGiovanna MP; Stern DF; Edgerton SM; Whalen SG; Moore D; Thor AD
J Clin Oncol; 2005 Feb; 23(6):1152-60. PubMed ID: 15718311
[TBL] [Abstract][Full Text] [Related]
29. EGFR gene and protein expression in breast cancers.
Park K; Han S; Shin E; Kim HJ; Kim JY
Eur J Surg Oncol; 2007 Oct; 33(8):956-60. PubMed ID: 17374474
[TBL] [Abstract][Full Text] [Related]
30. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
[TBL] [Abstract][Full Text] [Related]
31. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer.
Tsai MS; Shamon-Taylor LA; Mehmi I; Tang CK; Lupu R
Oncogene; 2003 Feb; 22(5):761-8. PubMed ID: 12569369
[TBL] [Abstract][Full Text] [Related]
32. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.
Aguilar Z; Akita RW; Finn RS; Ramos BL; Pegram MD; Kabbinavar FF; Pietras RJ; Pisacane P; Sliwkowski MX; Slamon DJ
Oncogene; 1999 Oct; 18(44):6050-62. PubMed ID: 10557094
[TBL] [Abstract][Full Text] [Related]
33. Src family kinases and HER2 interactions in human breast cancer cell growth and survival.
Belsches-Jablonski AP; Biscardi JS; Peavy DR; Tice DA; Romney DA; Parsons SJ
Oncogene; 2001 Mar; 20(12):1465-75. PubMed ID: 11313890
[TBL] [Abstract][Full Text] [Related]
34. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers.
Srinivasan R; Gillett CE; Barnes DM; Gullick WJ
Cancer Res; 2000 Mar; 60(6):1483-7. PubMed ID: 10749108
[TBL] [Abstract][Full Text] [Related]
35. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
Tan M; Grijalva R; Yu D
Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638
[TBL] [Abstract][Full Text] [Related]
36. Tyrosine phosphorylation of PP2A is regulated by HER-2 signalling and correlates with breast cancer progression.
Wong LL; Chang CF; Koay ES; Zhang D
Int J Oncol; 2009 May; 34(5):1291-301. PubMed ID: 19360341
[TBL] [Abstract][Full Text] [Related]
37. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study.
Mizell J; Smith M; Li BD; Ampil F; Chu QD
Ann Surg Oncol; 2009 Oct; 16(10):2711-6. PubMed ID: 19593633
[TBL] [Abstract][Full Text] [Related]
39. Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features.
Ansquer Y; Mandelbrot L; Lehy T; Salomon L; Dhainaut C; Madelenat P; Feldmann G; Walker F
Anticancer Res; 2005; 25(6C):4535-41. PubMed ID: 16334138
[TBL] [Abstract][Full Text] [Related]
40. Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells.
Sepp-Lorenzino L; Eberhard I; Ma Z; Cho C; Serve H; Liu F; Rosen N; Lupu R
Oncogene; 1996 Apr; 12(8):1679-87. PubMed ID: 8622888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
